DEMSER

This brand name is authorized in United States. It is also authorized in Japan, UK.

Active ingredients

The drug DEMSER contains one active pharmaceutical ingredient (API):

1	Metirosine UNII DOQ0J0TPF7 - METYROSINE
	Metirosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.
	Read more about Metirosine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DEMSER Capsule	MPI, US: SPL/Old	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
C02KB01	Metirosine	C Cardiovascular system → C02 Antihypertensives → C02K Other antihypertensives → C02KB Tyrosine hydroxylase inhibitors
Discover more medicines within C02KB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	199323
JP	医薬品医療機器総合機構	2190038M1024
US	FDA, National Drug Code	25010-305